Prevalence of Mood and Anxiety Disorders in Adult Patients With Pulmonary Langerhans Cell Histiocytosis

Study Overview
=================
Brief Summary
-----------------
Pulmonary Langerhans cell histiocytosis (PLCH) is a rare disease, of unknown etiology, that occurs almost exclusively in smokers.The clinical experience suggests a high prevalence of anxiety symptoms and an addictive profile. However, no study to date has precisely investigated the prevalence of co-morbid psychiatric disorders in this population.The aim of the study is to evaluate the prevalence of co-morbid psychiatric disorders in adult PLCH patients. This study should allow: to assess the prevalence of psychiatric disorders co-morbid in PLCH patients a targeted and more effective management of patients a better response rate to smoking and cannabis weaning, that represents a major goal for these patients.

Official Title
-----------------
Prevalence of Mood and Anxiety Disorders in Adult Patients With Pulmonary Langerhans Cell Histiocytosis: an Exploratory Study

Conditions
-----------------
Pulmonary Langerhans Cell Histiocytosis

Intervention / Treatment
-----------------
* Other: Evaluation of co-morbid psychiatric disorders


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients of 18 years of age or older with PLCH diagnosed at adulthood Patients affiliated to the French Health Care System Informed patients Exclusion Criteria: Patient unable to understand the interview (language barrier) Patient under guardianship or curatorship Patient under AME (French medical help for foreigners)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pulmonary Langerhans cell histiocytosis (PLCH)<br>Adults with pulmonary Langerhans cell histiocytosis | Other: Evaluation of co-morbid psychiatric disorders<br>* Added scales : Mini Internationnal Neuropsychiatric Interview Fagerström test DSM-5 Scale Additional dosage : - a urine sample will be taken to evaluate the presence of tobacco and nicotine breakdown products and the presence of various toxics Expired carbon monoxide for patients using nicotine substitutes<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients with at least one of the disorders detailed in the Mini International Neuropsychiatric Interview (MINI) test | The Mini-International Neuropsychiatric Interview (M.I.N.I.) is a structured diagnostic interview (40 minutes duration), exploring in a standardized way the main psychiatric disorders of Axis I of the DSM-IV TR (American Psychiatric Association), namely 14 items with a binary result for each specified disorder | at inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients with at least one comorbid addictive disorder among: tobacco, alcohol, cannabis, benzodiazepines, cocaine, opiates | Definition and diagnosis of addictive disorder will be assessed with Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) | at inclusion | 
| Proportion of patients with active tobacco consumption with or without comorbid psychiatric disorder | Tobacco consumption will be assessed by Fagerström survey and DSM-5, cotinine in urine quantification and expired carbon monoxide for patients using nicotine substitutes. Fargerstrom test evaluates the dependence on cigarettes from 0 to 10 (0 indicated a very low dependence and 10 a very strong dependence) | at inclusion | 
| Proportion of patients with persistent tobacco consumption despite nicotine replacement treatment | Tobacco consumption will be assessed by Fagerström survey and DSM-5 and expired carbon monoxide for patients with nicotine substitutes | at inclusion | 
| Number of previous tobacco weaning episodes and co-morbid psychiatric disorders |  | at inclusion | 
| Number of co-morbid psychiatric disorders |  | at inclusion | 
| Factors associated with psychiatric disorders as assessed by Mini International Neuropsychiatric Interview (MINI) test | The Mini-International Neuropsychiatric Interview (M.I.N.I.) is a structured diagnostic interview (40 minutes duration), exploring in a standardized way the main psychiatric disorders of Axis I of the DSM-IV TR (American Psychiatric Association), namely 14 items with a binary result for each specified disorder | at inclusion |